ImmuPharma shares surge 20% as P140 partnering talks advance

ImmuPharma PLC (AIM:IMM, FRA:25I) shares jumped 20% to 5.48p after the AIM-listed specialist drug discovery and development company said it is progressing discussions with a number of potential partners for its P140 autoimmune technology platform, including under signed confidentiality agreements, as it targets a value-enhancing licensing deal in 2026. The company's management team attended the Bio-Europe Spring healthcare conference in Lisbon this week, where a number of meetings were held in relation to P140, which ImmuPharma describes as a core value driver for the business.